AC Immune SA ( (ACIU) ) has shared an update.
On April 30, 2025, AC Immune SA released its interim financial results for the first quarter ending March 31, 2025. The company reported a total revenue of CHF 990,000, with an operating loss of CHF 19.37 million, slightly improved from the previous year’s loss of CHF 20.07 million. Despite the financial loss, the company’s focus remains on advancing its pipeline of treatments for neurodegenerative diseases, which is crucial for its long-term growth and market positioning.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
AC Immune SA’s stock score is constrained by its financial performance, characterized by net losses despite improving revenue and cash flow management. Technical analysis reveals a bearish trend with oversold conditions, and valuation metrics highlight profitability challenges with a negative P/E ratio. The company must improve profitability and market sentiment to drive stock performance.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a Swiss-based biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases. The company specializes in creating therapies for conditions such as Alzheimer’s disease, leveraging its proprietary technology platforms to develop a range of therapeutic and diagnostic products.
YTD Price Performance: -40.35%
Average Trading Volume: 200,746
Technical Sentiment Signal: Buy
Current Market Cap: $168.2M
See more data about ACIU stock on TipRanks’ Stock Analysis page.